Search results for "Psoriasis"

showing 10 items of 193 documents

A real-world economic analysis of biologic therapies for moderate-to-severe plaque psoriasis in Italy: results of the CANOVA observational longitudin…

2021

AbstractBackgroundPsoriasis is a chronic immune-mediated inflammatory skin disease which can also involve joints. It is often associated with burdensome comorbidities which negatively impact prognosis and quality of life (QoL). Biologic agents have been shown to be effective in controlling disease progression, but their use is associated with higher costs compared with traditional systemic treatments. The economic analysis of the CANOVA (EffeCtiveness of biologic treAtmeNts for plaque psOriasis in Italy: an obserVAtional longitudinal study of real-life clinical practice) study aims to assess the costs and cost-effectiveness of biologics in a real-world context in Italy.MethodsThe annualised…

Response ratemedicine.medical_specialtyCost per responderBiologicCostIxekizumabLongitudinal StudieContext (language use)Secukinumab.Severity of Illness IndexAntibodiesIndirect costsSettore MED/35Quality of lifeInternal medicinePsoriasisUstekinumabMonoclonalAdalimumab; Ixekizumab; Antibodies Monoclonal; Longitudinal Studies; Quality of Life; Psoriasis; Treatment Outcome; Severity of Illness Index; Italy; Humans; Biological Therapy; Ustekinumab; Secukinumab; Response rate; Real-world; Ixekizumab; Cost per responder; BiologicmedicineAdalimumabHumansPsoriasisLongitudinal Studieshealth care economics and organizationsSecukinumabPsoriasiAdalimumab; Biologic; Cost per responder; Costs; Ixekizumab; Real-world; Response rate; Secukinumab; Ustekinumab; Antibodies Monoclonal; Biological Therapy; Humans; Italy; Longitudinal Studies; Severity of Illness Index; Treatment Outcome; Psoriasis; Quality of Lifebusiness.industryHealth PolicyResearchAdalimumabAntibodies Monoclonalmedicine.diseaseCostsBiological TherapyIxekizumabTreatment OutcomeReal-worldItalyQuality of LifeSecukinumabUstekinumabPublic aspects of medicineRA1-1270Settore MED/35 - MALATTIE CUTANEE E VENEREEbusinessHumanmedicine.drugBMC Health Services Research
researchProduct

Decreased SAPK/JNK signalling affects cytokine release and STAT3 activation in psoriatic fibroblasts.

2015

STAT3 Transcription FactorMAP Kinase Signaling Systemmedicine.medical_treatmentDermatologyBiochemistryp38 Mitogen-Activated Protein KinasesPsoriasismedicineSapk jnkHumansPsoriasisPhosphorylationSTAT3Molecular BiologyStat3 activationMitogen-Activated Protein Kinase 1Mitogen-Activated Protein Kinase 3biologyChemistryInterleukin-6Tumor Necrosis Factor-alphaInterleukin-8JNK Mitogen-Activated Protein KinasesTranscription Factor RelAFibroblastsmedicine.diseaseSignallingCytokineCase-Control StudiesCancer researchbiology.proteinPhosphorylationTumor necrosis factor alphaExperimental dermatology
researchProduct

SAT0374 IL-36A Axis is Modulated in Patients with Primary Sjogren's Syndrome and Implicated in the Regulation of Gamma-Delta T Cells Immune Functions

2015

Background IL-36a is a cytokine that predominantly acts on naive CD4+ T cells and gamma-delta T cells via the IL-36 receptor. IL-36a has been recently demonstrated to be involved in human disease, such as psoriasis, by modulating innate and adaptive immune responses. Objectives In this study we aimed to investigate the expression of IL-36 axis and to assess the role of γδ T cells in patients with primary Sjogren9s syndrome (pSS). Methods Blood and minor labial salivary glands (MSG) biopsies were obtained from 35 pSS and 20 nSS patients. Serum IL-36a was assayed by ELISA. IL-36a, IL-36R, IL-36RA, IL-38, IL-22, IL-17, IL-23p19, expression in MSGs was assessed by rt-PCR and tissue IL-36a and I…

Salivary glandmedicine.diagnostic_testCD68medicine.medical_treatmentImmunologyBiologymedicine.diseaseGeneral Biochemistry Genetics and Molecular BiologyFlow cytometrymedicine.anatomical_structureCytokineImmune systemRheumatologyPsoriasisImmunologymedicineImmunology and AllergyImmunohistochemistryReceptorAnnals of the Rheumatic Diseases
researchProduct

Metabolic abnormalities associated with initiation of systemic treatment for psoriasis: evidence from the Italian Psocare Registry

2013

Objective To evaluate variations in laboratory parameters and diagnoses of selected clinical conditions up to 16 weeks after starting a new systemic psoriasis treatment for Psocare Registry enrollees. Design Prospective cohort study. Setting Italian public referral centres for psoriasis treatment. Patients First-time recipients (n = 10,539) of continuous systemic psoriasis treatment for at least 16 weeks. Main outcome measure Mean variations in (weeks 8 and 16) and proportions of patients reaching a clinically meaningful increase in serum levels (week 16) of total and low-density lipoprotein cholesterol, triglycerides, aspartate amino transferase, alanine amino transferase and creatinine, a…

Settore MED/35 - Malattie Cutanee E VenereePSORIASISTHERAPY
researchProduct

Cambios en las tendencias de la prescripción y causas de la interrupción en los tratamientos biológicos indicados en la psoriasis durante los primero…

2020

Resumen Antecedentes y objetivos Las guias sobre el tratamiento de la psoriasis habitualmente no incluyen las recomendaciones acerca de cual debe ser la primera linea de tratamiento sistemico o biologico. Los objetivos de este estudio fueron describir las tendencias en la prescripcion del primer farmaco biologico y comparar la retirada de los farmacos y las tasas de efectos adversos a lo largo de los 10 anos de seguimiento. Material y metodos Se utilizo el registro Biobadaderm para determinar cual fue el primer farmaco biologico indicado en pacientes con psoriasis naive para biologicos, asi como cual es la tasa de efectos adversos y los motivos de suspension de los farmacos. Los resultados …

TendenciaBiobadadermBiológicoPsoriasisTratamientoInterrupciónGeneral Medicine
researchProduct

Update on the Management of Pediatric Psoriasis: An Italian Consensus

2022

Introduction Psoriasis affects children with a considerable burden in early life. Treating pediatric psoriasis is challenging also because of the lack of updated specific guidelines. With the recent approval of several biologics for pediatric psoriasis and the ongoing COVID-19 pandemic, the management of young psoriatic patients is facing major changes. A revision of treatment recommendations is therefore needed. Methods In September 2021, a board of six Italian dermatologists convened to update treatment recommendations. The board issued evidence- and consensus-based statements covering relevant areas of pediatric psoriasis, namely: assessment of psoriasis severity, management of children …

Topical corticosteroidsAdolescentBiologicSystemic therapyCorticosteroid-sparingHealth-related quality of lifePediatric psoriasisDermatologyBiologicsAdolescentsPlaque psoriasiAdolescents; Biologics; Children; Corticosteroid-sparing; Health-related quality of life; Pediatric psoriasis; Plaque psoriasis; Systemic therapy; Topical corticosteroidsSettore MED/35Pediatric psoriasiPlaque psoriasisSettore MED/35 - MALATTIE CUTANEE E VENEREEChildren
researchProduct

Calidad de vida en los pacientes con psoriasis

2015

La psoriasis en una enfermedad sistémica crónica que conlleva exacerbaciones y remisiones a lo largo de la vida del paciente .Sólo se conocía la artropatía psoriásica como otra entidad nosológica asociada a la psoriasis cutánea. Sin embargo, en la actualidad se conoce ampliamente otras enfermedades relacionadas, patologías orgánicas, como es la enfermedad cardiovascular englobando en ella a todos sus factores de riesgo, así como patologías de la esfera psíquica que con frecuencia se manifiestan en estos pacientes. Estas patologías asociadas, ha cambiado de forma importante el abordaje que el dermatólogo debe hacer del paciente con psoriasis, llevando a cabo una visión integral desde el punt…

UNESCO::CIENCIAS MÉDICAScalidad de vidapsoriasis:CIENCIAS MÉDICAS [UNESCO]
researchProduct

Differential Effects of Biologics on Psoriasis-Related Vascular Inflammation and Risk of Thrombosis

2020

Programa Estatal de I+D+i Orientada a los Retos de la Sociedad from Ministerio de Ciencia, Innovación y Universidades and European Regional Development Fund (Spain) [RTI2018-094436-B-I00]; Ministerio de Sanidad y Consumo CIBERehd (Spain) [CB06/04/0071]; Generalitat Valenciana (Spain) [PROMETEO/2018/141]; Proyectos Grupos Emergentes [GV/2019/043]; and Universidad Europea (Spain) (2018/UEM32 and 2019/UEM29]. 8.551 JCR (2020) Q1, 4/69 Dermatology 1.951 SJR (2020) Q1, 54/438 Biochemistry No data IDR 2020 UEV

Vasculitis0301 basic medicinemedicine.medical_specialtyEnfermedad cardiovascularImiquimodCell CommunicationDermatologyBiochemistryMiceTrombosis03 medical and health sciences0302 clinical medicinePsoriasis Area and Severity IndexPsoriasisProductos biológicosLeukocytesmedicineAnimalsHumansPsoriasisMolecular BiologyBody surface areaBiological ProductsImiquimodTumor Necrosis Factor-alphabusiness.industryEndothelial CellsThrombosisCell BiologyDermatology Life Quality Indexmedicine.diseaseDermatologyThrombosis030104 developmental biology030220 oncology & carcinogenesisMethotrexatebusinessEnfermedad de la pielMacemedicine.drugJournal of Investigative Dermatology
researchProduct

Vitamin d and psoriasis pathology in the mediterranean region, valencia (Spain)

2014

Vitamin D has important immunomodulatory effects on psoriasis in the Mediterranean region. To measure vitamin D intake in subjects with and without psoriasis, and to find an association with relevant clinical features, a case-control study was performed using cases (n = 50, 50% participation rate) clinically diagnosed with psoriasis and 200 healthy subjects (39.5% participation rate), leaving a final sample of 104 people. A survey was conducted using a food frequency questionnaire and clinical histories. Cases and controls were compared using univariate and multivariate analyses. We observed insufficient intake of cholecalciferol (vitamin D3) or ergocalciferol (vitamin D2) for both cases an…

VitaminAdultMalemedicine.medical_specialtyVitaminesHealth Toxicology and MutagenesisPopulationlcsh:Medicinevitamin Dvitamin D deficiencyArticlechemistry.chemical_compoundYoung AdultPsoriasisInternal medicineVitamin D and neurologymedicineOdds RatioHumansMediterranean regioneducationCholecalciferoleducation.field_of_studybusiness.industrylcsh:RPublic Health Environmental and Occupational HealthPellOdds ratiopsoriasisMiddle Agedmedicine.diseaseVitamin D DeficiencyDermatologiaEndocrinologychemistrySpainCase-Control StudiesErgocalciferolsFemaleMetabolic syndromebusinessCholecalciferoldiet
researchProduct

Nuevas perspectivas en el abordaje terapéutico de la psoriasis

2014

En la actualidad las enfermedades inflamatorias crónicas de la piel, como la psoriasis, tienen un impacto significativo en cuanto a la calidad de vida de los pacientes y sus familias, además de representar una carga económica considerable. Se estima que aproximadamente el 3% de la población mundial sufre psoriasis. Esta patología presenta tres componentes característicos: un desequilibrio entre la respuesta inmune local y sus mecanismos reguladores, una respuesta inflamatoria exagerada y una renovación epidérmica incrementada. A pesar del efecto beneficioso que ha supuesto la introducción de las nuevas aunque costosas terapias biológicas en el tratamiento sistémico de la psoriasis, el metot…

adenosinafibroblastosinflamaciónUNESCO::CIENCIAS MÉDICASpsoriasis:CIENCIAS MÉDICAS [UNESCO]
researchProduct